Tag: self-administered parenteral market growth

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Self-Administered Parenteral Market Expected to Grow Between 2025 And 2029?

The market size for self-administered parenteral treatments has seen substantial growth lately. It is anticipated to expand from $24.57 billion in 2024 to $25.84 billion in 2025, illustrating a compound annual growth rate (CAGR) of 5.2%. This growth in the previous period is due to an increase in chronic illnesses, an aging demographic, government strategies, patient awareness and support initiatives, along with a surge in bone disorder cases.

The market for self-administered parenterals is projected to experience consistent expansion in the forthcoming years. It is predicted to reach a valuation of $30.83 billion in 2029, with a compound annual growth rate (CAGR) of 4.5%. The uptick during the forecast period is largely attributed to the growing preference amongst patients for home healthcare, telemedicine, remote patient monitoring, patient education and support initiatives, as well as the rise of personalized medicine. Key trends anticipated during the forecast period encompass the incorporation of digital health solutions, the development of customized drug delivery systems, the emergence of targeted therapies, and advancements in biologics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

What Are the Core Growth Drivers Propelling the Self-Administered Parenteral Market Forward?

The escalation in cases of chronic ailments is anticipated to fuel the expansion of the self-administered parenteral market. Chronic ailments are enduring health issues that usually develop gradually over time and typically require constant management and treatment. Self-administered parenteral products are utilized in the control of chronic diseases to handle treatment independently, which can notably enhance compliance in contrast to oral medication. For instance, come January 2023, as per the data from the National Institutes of Health, a US-based government entity, it is projected that in folks aged 50 or over, the count of individuals with at least one chronic ailment will see a rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Consequently, the escalating prevalence of chronic ailments is spurring the growth of the self-administered parenteral market.

What Segment Types Define the Self-Administered Parenteral Market Structure?

The self-administered parenteralmarket covered in this report is segmented –

1) By Product: Pre-Filled Syringes; Autoinjectors; Pen Injectors; Other Products

2) By Usage: Disposable; Reusable

3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Home Healthcare Providers; Specialty Clinics; Other Distribution Channels

4) By Application: Cardiovascular Diseases; Diabetes; Osteoporosis; Pain Management; Hormone Replacement; Other Applications

Subsegments:

1) By Pre-Filled Syringes: Glass Pre-Filled Syringes; Plastic Pre-Filled Syringes

2) By Autoinjectors: Disposable Autoinjectors; Reusable Autoinjectors

3) By Pen Injectors: Insulin Pen Injectors; Growth Hormone Pen Injectors; Other Pen Injectors

4) By Other Products: Infusion Pumps; Needle-Free Injectors; Combination Devices

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13927&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Self-Administered Parenteral Market?

North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing theSelf-Administered Parenteral Industry Evolution?

Prominent businesses in the self-administered parenteral market are concentrating their efforts on creating innovative products like the UDENYCA autoinjector. This emphasis is to give more selection and autonomy, which in turn makes treatment more available to patients. An autoinjector is a sophisticated medical device that administers a specific drug dosage. It is an instinctive design where drug administration is initiated effortlessly and consistently when pushed onto the skin. In May 2023, Coherus BioSciences Inc., a biotech company based in the US, introduced the UDENYCA autoinjector, a self-administered parenteral medicine in the US. This single-dose, prefilled autoinjector provides an alternative pegfilgrastim administration method. It is ingeniously designed to initiate drug distribution when pushed onto the skin, ensuring a reliable and instantaneous complete pegfilgrastim dosage delivery. It also boasts numerous customer-friendly features facilitating successful delivery, such as quick dosage, intuitive design, dual coverage, usability at home and office, and reduces the risk of febrile neutropenia.

View the full report here:

https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

What Is the Definition of the Self-Administered Parenteral Market?

Self-administered parenteral refers to the administration of medication or substances into the body by oneself through injection methods. This method provides patients with greater autonomy and convenience, allowing them to manage the conditions in a more flexible and comfortable environment without the need for frequent visits to healthcare facilities.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13927

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Self-Administered Parenteral Market?

In recent times, the market size of self-administered parenteral has significantly expanded. The market is forecast to increase from $24.57 billion in 2024 to $26.04 billion in 2025, with a compound annual growth rate (CAGR) of 6.0%. The surge in growth witnessed in the historical period is due to factors such as an increase in chronic diseases, an aging population, governmental initiatives, patient education and support programs, and a rise in bone disorder cases.

What Growth Rate Is Forecasted for the Self-Administered Parenteral Market by 2029?

A consistent increase in the size of the self-administered parenteral market is predicted for the upcoming years, and it is projected to reach $31.18 billion in 2029, with a compound annual growth rate (CAGR) of 4.6%. Factors contributing to the growth during the forecast period include the rising preference of patients for home healthcare, advancements in telemedicine and remote patient monitoring, as well as initiatives aimed at patient education and support, and the expansion of personalized medicine. The forecast period will see trends like digital health solutions integration, customized drug delivery systems, the rise of targeted therapies, and breakthroughs in biologics.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

Which Key Companies Are Shaping the Future of the Self-Administered Parenteral Market?

Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG

Which Factors Are Driving Demand in the Self-Administered Parenteral Industry?

The upward trend in chronic disease incidents is projected to fuel the expansion of the self-administered parenteral market. Chronic diseases are enduring health issues that usually gradually develop and frequently necessitate continuous management and treatment. Self-administered parenteral products assist in the management of chronic diseases by enabling independent treatment, which can significantly enhance adherence compared to oral drugs. For example, the National Institutes of Health, a government agency based in the USA, projected in January 2023 that the number of individuals aged 50 or above with at least one chronic ailment is anticipated to rise by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Consequently, the escalating prevalence of chronic diseases is fostering the growth of the self-administered parenteral market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13927&type=smp

How Is the Self-Administered Parenteral Market Segmented by Several Divisions?

The self-administered parenteral market covered in this report is segmented –

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products

2) By Usage: Disposable, Reusable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels

4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Subsegments:

1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes

2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors

3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors

4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices

What are the Emerging Market Trends Driving the Growth of the Self-Administered Parenteral Industry?

Leading brands in the self-administered parenteral market are concentrating on the creation of cutting-edge products like the UDENYCA autoinjector, to give more options and power to the patients, consequently making the treatment more reachable. Defined as a medical tool, an autoinjector is crafted to administer a single dosage of a specific medication and is devised with a user-friendly layout that triggers prompt and dependable administration upon skin contact. For example, the US-based biotechnology firm, Coherus BioSciences Inc., unveiled the UDENYCA autoinjector, a self-administered parenteral drug in the US in May 2023. The UDENYCA Autoinjector is a prefilled autoinjector containing a single dose, offering an alternative method of administering pegfilgrastim to patients. It is designed with simplicity in mind, activating upon skin contact to ensure reliable and immediate delivery of a full pegfilgrastim dose. The device also provides numerous features catering to user convenience, including speedy dosing, effortless design, dual coverage, suitability for both home and office usage, and reduced risk of febrile neutropenia.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

Which Regions Are Driving Growth in the Self-Administered Parenteral Market?

North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13927

This Report Delivers Insight On:

1. How big is the self-administered parenteral market, and how is it changing globally?

2. Who are the major companies in the self-administered parenteral market, and how are they performing?

3. What are the key opportunities and risks in the self-administered parenteral market right now?

4. Which products or customer segments are growing the most in the self-administered parenteral market?

5. What factors are helping or slowing down the growth of the self-administered parenteral market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the self-administered parenteral industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has the Self-Administered Parenteral Market Growth Performance Trended Historically, And What Lies Ahead?

In the past few years, there has been robust growth in the self-administered parenteral market. The market’s size is predicted to surge from $24.57 billion in 2024 to $26.04 billion in 2025, signifying a Compound Annual Growth Rate (CAGR) of 6.0%. Historical growth can be traced back to factors such as an increase in chronic diseases, an aging population, government initiatives, patient education and support programs, in addition to the escalating incidences of bone disorders.

The market size of self-administered parenteral therapies is projected to observe robust growth over the coming years, ballooning to $31.18 billion in 2029 at a CAGR of 4.6%. Factors contributing to growth during the forecast period include the rising preference amongst patients for home healthcare, developments in telemedicine and remote patient supervision, initiatives focused on patient education and support, and the growth of personalized medicine. Noteworthy trends for the forecast period include the amalgamation of digital health solutions, custom drug delivery systems, the advent of targeted therapies, and advancements in biologics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Self-Administered Parenteral Market?

The rise in chronic diseases is anticipated to drive the expansion of the self-administered parenteral market in the future. Chronic diseases are enduring health conditions that typically progress gradually and often necessitate continuous management and treatment. Self-administered parenteral products are employed in treating chronic diseases independently, leading to a noticeable enhancement in adherence compared to orally administered medication. For example, in January 2023, the National Institutes of Health, a government agency in the US, projected that there will be a 99.5% increase in the population aged 50 or above with at least one chronic disease, from 71.522 million in 2020 to 142.66 million by 2050. Thus, the rising prevalence of chronic diseases is fuelling the expansion of the self-administered parenteral market.

What Segment Types Define the Self-Administered Parenteral Market Structure?

The self-administered parenteral market covered in this report is segmented –

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products

2) By Usage: Disposable, Reusable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels

4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Subsegments:

1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes

2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors

3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors

4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13927&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Self-Administered Parenteral Market?

North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Self-Administered Parenteral Market?

Firms ruling the self-administered parenteral market, such as Coherus BioSciences Inc, are putting their efforts towards the innovation of products like the UDENYCA autoinjector to supply more options and independence, hence making treatment more feasible for patients. An autoinjector is a medicinally constructed implement planned to distribute one dosage of a specific medication. This is a straightforward device that functions by applying pressure to the skin. Coherus BioSciences Inc, an American biotech firm, introduced the UDENYCA autoinjector, a self-administered parenteral drug in the US market in May 2023. With a preloaded single-dose autoinjector for pegfilgrastim, the UDENYCA aims to ensure a user-friendly, efficient, and reliable dosage delivery upon skin contact. It comes with features that ensure successful delivery like fast dosing, easy-to-understand design, dual coverage, suitability for at-home or office use, and lessens the danger of febrile neutropenia.

View the full report here:

https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

What Is the Definition of the Self-Administered Parenteral Market?

Self-administered parenteral refers to the administration of medication or substances into the body by oneself through injection methods. This method provides patients with greater autonomy and convenience, allowing them to manage the conditions in a more flexible and comfortable environment without the need for frequent visits to healthcare facilities.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13927

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theSelf-Administered Parenteral Market?

The rise in chronic illnesses is anticipated to fuel the expansion of the self-administered parenteral market. Chronic illnesses are persistent health problems that typically gradual progression and frequently necessitate ongoing management and therapy. Self-administered parenteral products, used for chronic disease management, enable patients to handle their treatment autonomously, leading to significantly greater adherence than oral medication. For instance, the National Institutes of Health, a US-based government agency, reported in January 2023 that the number of individuals 50 and above with at least one chronic disease is predicted to surge by 99.5% from 71.522 million in 2020 up to 142.66 million by 2050. Consequently, the escalating prevalence of chronic diseases acts as a growth driver for the self-administered parenteral market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

#What is the Projected CAGR for the Self-Administered Parenteral Market Size from 2025 to 2034?

The market size for self-administered parenteral therapies has seen significant expansion in the last few years. Anticipated growth is from $24.57 billion in 2024 to $26.04 billion in 2025, representing a compound annual growth rate (CAGR) of 6.0%. Factors contributing to this historical growth include the increasing prevalence of chronic illnesses, an aging demographic, government-led initiatives, patient awareness and support frameworks, and a surge in bone disorder cases.

Anticipations predict a consistent increase in the size of the self-administered parenteral market in the upcoming years. By 2029, it’s projected to reach $31.18 billion, fueled by a compound annual growth rate (CAGR) of 4.6%. This progression over the forecast period is tied to growing patient inclination towards home healthcare, advancements in telemedicine and remote patient monitoring, heightened patient education, and burgeoning personalized medicine. Key trends forecasted within this period involve the incorporation of digital health solutions, personalized drug delivery systems, the rise of targeted therapies, and biologics advancements.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13927

Which Upcoming Market Trends and Innovations Are Set to Influence theSelf-Administered Parenteral Market’s Path Forward?

Leading firms in the self-administered parenteral market are aiming to develop revolutionary products such as the UDENYCA autoinjector. This is to offer more options and control, and ultimately make treatments more accessible for patients. Essentially, an autoinjector is a medical tool designed to deliver a one-time dose of a specific drug. Its design is easy to understand and it can be activated instantly and reliably by pressing it against the skin. For example, in May 2023, US biotech firm Coherus BioSciences Inc. released the UDENYCA autoinjector, a self-administered parenteral medication in the US. This is a single-dose, prefilled autoinjector meant to offer patients an alternative way to administer pegfilgrastim. It is designed in such a way that it can be quickly and reliably activated by pressing it against the skin, ensuring the immediate delivery of a full dose of pegfilgrastim. Besides, this autoinjector offers several features that make it user-friendly and encourage successful delivery. It offers rapid dosing, an intuitive design, dual-coverage, it can be used at home or in the office, and it minimizes the risk of febrile neutropenia.

Who Are the Dominant Market Players Pushing the Boundaries of theSelf-Administered Parenteral Market?

Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

What Are the Core Segments of the Self-Administered Parenteral Market, and How Do They Contribute to Growth?

The self-administered parenteral market covered in this report is segmented –

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products

2) By Usage: Disposable, Reusable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels

4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Subsegments:

1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes

2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors

3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors

4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13927&type=smp

What Regions Are Dominating the Self-Administered Parenteral Market Growth?

North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Self-Administered Parenteral Market 2025, By The Business Research Company:

Residential Substance Abuse And Mental Health Facilities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

Payer Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/payer-services-global-market-report

Platform as a service (PaaS) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/platform-as-a-service-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the self-administered parenteral market grown over the years?

The self-administered parenteral market has seen strong growth, forecasted to increase from $24.57 billion in 2024 to $26.04 billion in 2025 at a CAGR of 6.0%. Factors behind this growth include a rise in chronic diseases, an aging population, government healthcare initiatives, patient education programs, and the increasing prevalence of bone disorders.

What Is the forecasted market size and growth rate for the self-administered parenteral market?

The self-administered parenteral market is projected to grow steadily, reaching $31.18 billion in 2029, with a 4.6% CAGR. Growth is attributed to rising home healthcare adoption, telemedicine expansion, patient education initiatives, and personalized medicine advancements. Key trends include digital health integration, customized drug delivery systems, targeted therapies, and biologics innovation.

Get your self-administered parenteral market report here!

https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

What are the major factors driving growth in the self-administered parenteral market?

The escalation in chronic disease cases is anticipated to fuel the expansion of the self-administered parenteral market. Chronic diseases are enduring health problems that typically advance sluggishly over time, often necessitating continuous management and therapy. Self-administered parenteral products play a crucial role in managing chronic diseases, facilitating treatment management independently and potentially enhancing adherence compared to oral medication. For example, in January 2023, the National Institutes of Health, a U.S. government agency, projected that the number of individuals aged 50 and above with at least one chronic disease would surge by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Hence, the increasing prevalence of chronic diseases is propelling the expansion of the self-administered parenteral market.

What key areas define the segmentation of the global self-administered parenteral Market?

The self-administered parenteral market covered in this report is segmented –

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products

2) By Usage: Disposable, Reusable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels

4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Subsegments:

1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes

2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors

3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors

4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

What are the top market players propelling the growth of the self-administered parenteral industry?

Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG

What are the key trends shaping the future of the self-administered parenteral market?

Leading businesses in the self-administered parenteral market, such as Coherus BioSciences Inc., are seeking to evolve with innovative product developments like the UDENYCA autoinjector, aiming to give more options and power to the patients, thereby enhancing the accessibility of the treatments. An autoinjector, by design, is a medical instrument developed to deliver a specific one-time drug dose, and the administration of the same is instantly and reliably initiated when pushed against the skin. To put it in context, in May 2023, Coherus BioSciences Inc, a biotech firm based in the US, premiered the UDENYCA autoinjector, a type of self-administered parenteral drug in the United States. The UDENYCA Autoinjector is a single-use, prefilled device allowing an alternative administering method for pegfilgrastim. The design is user-friendly, permitting reliable, and immediate delivery of the full pegfilgrastim dose upon push-on-skin activation. The autoinjector boasts several advantageous features leading to successful delivery, such as rapid dosing, a straightforward design, dual coverage, flexibility for home or office use, and reduced risk of febrile neutropenia.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13927

What regions are dominating the self-administered parenteral market growth?

North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Residential Substance Abuse And Mental Health Facilities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

Payer Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/payer-services-global-market-report

Platform as a service (PaaS) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/platform-as-a-service-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Will the CAGR of the Self-Administered Parenteral Market Influence Its Overall Growth by 2034?

In recent years, the market size for self-administrated parenteral products has increased robustly. A rise from $24.57 billion in 2024 to $26.04 billion in 2025 is expected, representing a compound annual growth rate (CAGR) of 6.0%. The expansion during the historical period can be traced back to factors like the escalating prevalence of chronic diseases, the aging population, government policies, initiatives aimed at patient education and support programs, and an increase in cases of bone ailments.

The market for self-administered parenteral treatments is predicted to see consistent expansion in the coming years, reaching a worth of $31.18 billion in 2029, with a compound annual growth rate (CAGR) of 4.6%. This growth during the projected period can be ascribed to factors such as rising patient inclination towards home healthcare, telemedicine, remote patient surveillance, patient instruction and support initiatives, and the expansion of personalized medicine. Key trends during this period comprise the incorporation of digital health solutions, personalized drug delivery systems, the onset of targeted therapies, and advancements in biologics.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Self-Administered Parenteral Market?

The escalation in chronic disease cases is anticipated to fuel the expansion of the self-administered parenteral market. Chronic diseases are enduring health problems that typically advance sluggishly over time, often necessitating continuous management and therapy. Self-administered parenteral products play a crucial role in managing chronic diseases, facilitating treatment management independently and potentially enhancing adherence compared to oral medication. For example, in January 2023, the National Institutes of Health, a U.S. government agency, projected that the number of individuals aged 50 and above with at least one chronic disease would surge by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Hence, the increasing prevalence of chronic diseases is propelling the expansion of the self-administered parenteral market.

Explore Comprehensive Insights Into The Global Self-Administered Parenteral Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

Who Are the Leading Companies Pioneering Change in the Self-Administered Parenteral Market?

Major companies operating in the self-administered parenteral market report are:

• Pfizer Inc._x000D_

• Johnson & Johnson_x000D_

• Merck & Co. Inc._x000D_

• Sanofi S.A._x000D_

• AstraZeneca PLC_x000D_

What Are the Most Significant Trends Transforming the Self-Administered Parenteral Market Today?

Leading businesses in the self-administered parenteral market, such as Coherus BioSciences Inc., are seeking to evolve with innovative product developments like the UDENYCA autoinjector, aiming to give more options and power to the patients, thereby enhancing the accessibility of the treatments. An autoinjector, by design, is a medical instrument developed to deliver a specific one-time drug dose, and the administration of the same is instantly and reliably initiated when pushed against the skin. To put it in context, in May 2023, Coherus BioSciences Inc, a biotech firm based in the US, premiered the UDENYCA autoinjector, a type of self-administered parenteral drug in the United States. The UDENYCA Autoinjector is a single-use, prefilled device allowing an alternative administering method for pegfilgrastim. The design is user-friendly, permitting reliable, and immediate delivery of the full pegfilgrastim dose upon push-on-skin activation. The autoinjector boasts several advantageous features leading to successful delivery, such as rapid dosing, a straightforward design, dual coverage, flexibility for home or office use, and reduced risk of febrile neutropenia.

Secure Your Global Self-Administered Parenteral Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

What Are the Core Segments of the Self-Administered Parenteral Market, and How Do They Contribute to Growth?

The self-administered parenteral market covered in this report is segmented –

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products

2) By Usage: Disposable, Reusable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels

4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Subsegments:

1) By Pre-Filled Syringes: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes

2) By Autoinjectors: Disposable Autoinjectors, Reusable Autoinjectors

3) By Pen Injectors: Insulin Pen Injectors, Growth Hormone Pen Injectors, Other Pen Injectors

4) By Other Products: Infusion Pumps, Needle-Free Injectors, Combination Devices

Which Regions Are Leading the Charge in Self-Administered Parenteral Market Development?

North America was the largest region in the self-administered parenteral market in 2024. The regions covered in the self-administered parenteral market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Definition of the Self-Administered Parenteral Market Impacting Future Growth?

Self-administered parenteral refers to the administration of medication or substances into the body by oneself through injection methods. This method provides patients with greater autonomy and convenience, allowing them to manage the conditions in a more flexible and comfortable environment without the need for frequent visits to healthcare facilities.

Browse Through More Similar Reports By The Business Research Company:

Residential Substance Abuse And Mental Health Facilities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

Payer Services Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/payer-services-global-market-report

Platform as a service (PaaS) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/platform-as-a-service-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: